Zobrazeno 1 - 10
of 651
pro vyhledávání: '"C. Codina"'
Autor:
M Bosch Peligero, G Ginovart Galiana, A Arias Martinez, A Siles Baena, M Ocaña Rico, R Porta Ribera, A Martín Val, L Laguna Marmol, E Terricabras Mas, C Codina Jiménez, C Quiñones Ribas
Publikováno v:
Section 4: Clinical pharmacy services.
Autor:
E Valls, S Marin, C Codina-Jiménez, E Terricabras, L Estrada, A Bocos-Baelo, C García-Castiñeira, G Cardona, À Andreu, C Quiñones
Publikováno v:
Section 5: Patient safety and quality assurance.
Autor:
A Bocos Baelo, C García-Castiñeira, A Vilariño, A Martin, A Arias, C Codina–Jiménez, L Estrada, E Terricabras, E Valls, S Marin, C Quiñones
Publikováno v:
Section 5: Patient safety and quality assurance.
Publikováno v:
Section 4: Clinical pharmacy services.
Autor:
L Estrada, S Marin, G Cardona, L Carabias-Ané, A Morales, E Terricabras, A Bocos-Baelo, C García-Castiñeira, C Codina-Jiménez, E Valls, C Quiñones
Publikováno v:
Section 4: Clinical pharmacy services.
Autor:
I Vilimelis, A Pérez-Ricart, M Bosch Peligero, A Calvo, E Valls Sánchez, C Codina-Jiménez, S Marin, JM Suñé Negre, C Quiñones Ribas, JC Giménez-Juárez
Publikováno v:
Section 5: Patient safety and quality assurance.
Autor:
I Vilimelis, A Pérez-Ricart, M Bosch Peligero, A Calvo, C Codina-Jiménez, E Valls Sánchez, JM Suñé Negre, C Quiñones Ribas, JC Giménez-Juárez
Publikováno v:
Section 5: Patient safety and quality assurance.
Autor:
C Codina Jiménez, S Marin, M Álvarez, E Terricabras, L Estrada, E Valls, C García-Castiñeira, A Bocos-Baelo, C Quiñones
Publikováno v:
Section 4: Clinical pharmacy services.
Autor:
A Vilariño Seijas, C Codina Jiménez, E Valls Sánchez, L Carabias Ané, G Cardona Peitx, C Quiñones Ribas, A Morales Triadó
Publikováno v:
Section 5: Patient Safety and Quality assurance.
Background and importance A large number of patients with systemic autoimmune diseases (SAD) do not respond or relapse to firstline therapies. Current guidelines recommend the off-label use of rituximab for many severe refractory SAD even though most
Publikováno v:
ePoster.
Introduction/Background Primary surgical cytoreduction followed by systemic chemotherapy is the preferred initial management for women with stage III or IV ovarian cancer. Patients considered unresectable due to the location and volume of disease inv